Past, Present and Further Looking for Therapeutic Management of Pancreatic Ductal Adenocarcinoma (2nd Edition)
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 31 October 2025 | Viewed by 215
Special Issue Editors
2. Pancreatic Surgery Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy
Interests: pancreatic cancer; periampullary tumors; ampullary carcinoma; general surgery; pancreatectomy; pancreatic surgery
Special Issues, Collections and Topics in MDPI journals
Interests: pancreatic cancers; pancreatic ductal adenocarcinoma; IPMN; histopathology; primary cell cultures; molecular biology; molecular pathology; laser microdissection; miRNAs; oncomarkers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pancreatic ductal adenocarcinoma (PDAC) still represents one of the cancers with the poorest prognosis. Currently, surgery remains the only curative treatment for PDAC, but the 5-year survival rate of resected patients is only about 20–25%. During the last decades, some improvements have been achieved in terms of chemotherapic treatment, with the development of specific multi-chemotherapic regimens (FOLFIRINOX, gemcitabine + nab-paclitaxel, PAX-G) that have improved oncological results if compared with historically adopted single chemotherapic agents (gemcitabine). Moreover, if historically, for resectable PDAC, the gold standard strategy was surgery followed by adjuvant therapy, currently the scenario is radically changing. More often, the idea is to perform neoadjuvant therapy followed by surgery and, eventually, adjuvant treatment. The rationale for this approach is the early management of micro-metastatic disease and to allow a better selection of patient candidates for surgery. Thus, the analyses of old, recent, and upcoming molecular markers could change the landscape of clinical management of the PDAC. However, preclinical models of PDAC, including all different levels of models approaching PDAC, will be appreciated in order to show experimental attempts to validate the role of biomolecular markers and their affinity for chemotherapy. Indeed, other new frontiers of PDAC treatment, including phytotherapy and theragnostic molecules, are welcome.
This Special Issue aims to evaluate all the novel therapeutic approaches for the management of PDAC (resectable, borderline-resectable, locally advanced, and metastatic disease). Pre-clinical and clinical studies focusing on this topic will be included in this Special Issue.
Dr. Gennaro Nappo
Dr. Niccola Funel
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pancreatic cancer
- pancreatic ductal adenocarcinoma
- treatment pancreatic cancer
- chemotherapy pancreatic cancer
- radiotherapy pancreatic cancer
- pancreatic cancer biology
- PDAC preclinical model
- biomolecular markers
- theragnostic molecules
- target therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
